PTAB Axes Patent Claims For Nektar Hemophilia Drug

By Andrew Karpan (August 2, 2021, 4:41 PM EDT) -- The Patent Trial and Appeal Board has found that claims in two polymer patents that cover a hemophilia treatment developed by Nektar Therapeutics are obvious in light of a collection of prior art.

In a pair of decisions that came down Friday, a three-judge panel at the patent board scratched out all the claims challenged by NOF Corp., a Japanese chemical company. The two patents were at issue in an infringement lawsuit Nektar lodged against Bayer Healthcare LLC in 2018, according to the decisions.

That suit was settled back in March, in a deal that came the same day as a...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!